Expression of concern
The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies
Paper Information
Record ID:
41687
Author(s):
Publication Date:
January 30, 2018
Retraction Date:
December 30, 2022
(2.9 years years ago)
Subjects:
Country:
🇨🇳 ChinaArticle Type:
Publisher:
PLoS
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Expression of concern Details
Retraction Reasons:
Nature of Retraction:
Expression of concern
Retraction Notice:
10.1371/journal.pone.0279960Citations (90)
90
Total Citations41
Post-Retraction(45.6%)
48
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
2
Within 30 days
12
Within 1 year
7
After 2+ years
901
Days since retraction (latest)
HER2: Biology, Definition, Diagnosis, and its Role in Cancers
Mina Sadat Naderi, Fereshteh Ameli, Sahand Golestanian
IntechOpen eBooks
Published: Jun 2025
901 days after retraction
Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers
Victoria M. Ettorre, Abdelrahman AlAshqar, Namrata Sethi et al. (4 authors)
Cancers
Open Access
Published: May 2025
882 days after retraction
Repurposing FDA-Approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-Grade Serous Ovarian Cancer Treatment
Vivek Podder, Rachel N. Grisham, Robert L. Coleman et al. (8 authors)
International Journal of Gynecological Cancer
Published: May 2025
853 days after retraction
HER2 Targeted Agents in Gynecologic Cancers: An Updated Review
Kendra Gee-Rodriguez, Amy Indorf, Elizabeth M. Swisher et al. (5 authors)
International Journal of Gynecological Cancer
Published: May 2025
853 days after retraction
Unveiling HER2 immunoexpression in canine hepatoid gland neoplasms: clinicopathological and morphological associations
Hassadin BOONSRIROJ, Sahatchai Tangtrongsup, Jirapat Arunorat et al. (5 authors)
International Journal of Veterinary Science and Medicine
Open Access
Published: Apr 2025
846 days after retraction
Exploring Zanidatamab’s efficacy across HER2-positive Malignancies: a narrative review
Warisha Kanwal, Kaneez Narjis, Sarah Musani et al. (12 authors)
BMC Cancer
Open Access
Published: Mar 2025
792 days after retraction
Enhancing the Antitumor Effect of MUC16 CART Cells in Ovarian Cancer: The Potential of Oncolytic Adenovirus
Qiuman Wang, Wofeng Liu, Yuanchun Fan et al. (9 authors)
Cancer Letters
Published: Feb 2025
764 days after retraction
Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction
Soo‐Yeon Hwang, Kyung‐Hwa Jeon, Hwa-Jong Lee et al. (12 authors)
eLife
Open Access
Published: Dec 2024
1 citation
1 citation
706 days after retraction
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer
Sa Deok Hong, Nar Bahadur Katuwal, Min Sil Kang et al. (9 authors)
International Journal of Molecular Sciences
Open Access
Published: Oct 2024
2 citations
2 citations
671 days after retraction
Synthesis and Biological Assessment of Chalcone and Pyrazoline Derivatives as Novel Inhibitor for ELF3-MED23 Interaction
Soo‐Yeon Hwang, Kyung‐Hwa Jeon, Hwa-Jong Lee et al. (12 authors)
Unknown Journal
Open Access
Published: Sep 2024
620 days after retraction
Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems
Qianhan Lin, Jiajia Li, Zulimire Abudousalamu et al. (7 authors)
International Journal of Nanomedicine
Open Access
Published: Sep 2024
5 citations
5 citations
611 days after retraction
Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment
Meduri Bhagyalalitha, Akshatha Handattu Shankaranarayana, Sethu Arun Kumar et al. (7 authors)
Bioorganic Chemistry
Published: Aug 2024
2 citations
2 citations
588 days after retraction
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak et al. (4 authors)
International Journal of Molecular Sciences
Open Access
Published: Jul 2024
9 citations
9 citations
578 days after retraction
Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing
Clara Diaz Garcia-Prada, Salima Atis, Jean‐Pierre Pouget et al. (4 authors)
Methods in cell biology
Published: Jun 2024
535 days after retraction
Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction
Soo‐Yeon Hwang, Kyung‐Hwa Jeon, Hwa-Jong Lee et al. (12 authors)
eLife
Open Access
Published: Jun 2024
522 days after retraction
Synthesis and Biological Assessment of Chalcone and Pyrazoline Derivatives as Novel Inhibitor for ELF3-MED23 Interaction
Soo‐Yeon Hwang, Kyung‐Hwa Jeon, Hwa-Jong Lee et al. (12 authors)
Unknown Journal
Open Access
Published: Jun 2024
522 days after retraction
Adding trastuzumab to carboplatin and paclitaxel improves overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcoma
Ting-Fang Lu, Lou Sun, Yu‐Hsiang Shih et al. (10 authors)
Research Square (Research Square)
Open Access
Published: May 2024
502 days after retraction
Prospects and challenges of CAR-T in the treatment of ovarian cancer
Biqing Chen, Jiaqi Liu
International Immunopharmacology
Published: Apr 2024
3 citations
3 citations
476 days after retraction
Human Epidermal Growth Factor Receptor 2 Overexpression/Amplification in Primary Ovarian Endometrioid Carcinoma
Chau M. Bui, Aviv Oren, Bonnie Balzer et al. (5 authors)
Applied immunohistochemistry & molecular morphology
Published: Apr 2024
475 days after retraction
Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer
Yoo‐Na Kim, Yun Soo Chung, Eunhyang Park et al. (5 authors)
Scientific Reports
Open Access
Published: Apr 2024
12 citations
12 citations
462 days after retraction
Synthesis and Biological Assessment of Chalcone and Pyrazoline Derivatives as Novel Inhibitor for ELF3-MED23 Interaction
Soo‐Yeon Hwang, Kyung‐Hwa Jeon, Hwa-Jong Lee et al. (12 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Mar 2024
431 days after retraction
Breast cancer: epidemiology, molecular classification, diagnostic and therapeutic management
Paulina Kaleta, Zuzanna Rzepka, Magdalena Janus et al. (4 authors)
Farmacja Polska
Open Access
Published: Feb 2024
400 days after retraction
Angio-Long Noncoding RNA MALAT1 (rs3200401) and MIAT (rs1061540) Gene Variants in Ovarian Cancer
Manal S. Fawzy, Afaf T. Ibrahiem, Dalia Mohammad Osman et al. (9 authors)
Epigenomes
Open Access
Published: Jan 2024
4 citations
4 citations
395 days after retraction
Pb-214/Bi-214-TCMC-Trastuzumab inhibited growth of ovarian cancer in preclinical mouse models
Abdullah Metebi, Nathan Kauffman, Lu Xu et al. (11 authors)
Frontiers in Chemistry
Open Access
Published: Jan 2024
6 citations
6 citations
391 days after retraction
Fallopian tube single cell analysis reveals myeloid cell alterations in high-grade serous ovarian cancer
Joshua Brand, Marcela Haro, Xianzhi Lin et al. (7 authors)
iScience
Open Access
Published: Jan 2024
1 citation
1 citation
389 days after retraction
Expression of Estrogen Receptor (ER), Progesterone Receptor (PR), Her2/neu in Various Types of Epithelial Ovarian Tumors
Fereshteh Ameli, Maryam Entezarian, Noraidah Masir et al. (4 authors)
Journal of Obstetrics Gynecology and Cancer Research
Open Access
Published: Jan 2024
1 citation
1 citation
388 days after retraction
17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications
Vid Mlakar, Isabelle Dupanloup, Fanny Gonzales et al. (6 authors)
Cancers
Open Access
Published: Jan 2024
6 citations
6 citations
378 days after retraction
Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer
Pooja Shukla, Kumudesh Mishra, Ratnakar Shukla et al. (8 authors)
Journal of Cancer Research and Therapeutics
Open Access
Published: Jan 2024
1 citation
1 citation
367 days after retraction
Resistance of HER2-expressing ovarian cancer to trastuzumab and mechanisms of overcoming resistance
Ryan McWhorter, Massimo Libra, Benjamin Bonavida
Elsevier eBooks
Published: Jan 2024
367 days after retraction
Molecular genetic markers of ovarian cancer tumor cells and their microenvironment, study methods, and clinical value: A review
M. A. Kalfa, Ilya O. Golovkin, Artem E. Lazarev et al. (6 authors)
Journal of Modern Oncology
Open Access
Published: Dec 2023
1 citation
1 citation
345 days after retraction
Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
Blair McNamara, Michelle Greenman, Nicole Pebley et al. (5 authors)
Molecules
Open Access
Published: Nov 2023
9 citations
9 citations
307 days after retraction
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
Blair McNamara, Levent Mutlu, Michelle Greenman et al. (5 authors)
Cancers
Open Access
Published: Aug 2023
6 citations
6 citations
227 days after retraction
Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
Blair McNamara, Yifan Chang, Ashley Goreshnik et al. (4 authors)
International Journal of Women s Health
Open Access
Published: Aug 2023
8 citations
8 citations
214 days after retraction
Human fallopian tube single-cell analysis reveals monocytic transcriptional and interaction changes in high-grade serous ovarian cancers
Joshua Brand, Marcela Haro, Xianzhi Lin et al. (6 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Jul 2023
198 days after retraction
Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches
Ivan Lučić, Matea Kurtović, Monika Mlinarić et al. (7 authors)
International Journal of Molecular Sciences
Open Access
Published: Jun 2023
3 citations
3 citations
178 days after retraction
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus
Zaid Taha, Mathieu J. F. Crupi, Nouf Alluqmani et al. (14 authors)
Frontiers in Immunology
Open Access
Published: Apr 2023
5 citations
5 citations
110 days after retraction
Integrating antibody drug conjugates in the management of gynecologic cancers
Anca Chelariu-Raicu, Sven� Mahner, Kathleen N. Moore et al. (5 authors)
International Journal of Gynecological Cancer
Published: Mar 2023
22 citations
22 citations
61 days after retraction
The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells
Alexandra Kollara, Brian D. Burt, Maurice Ringuette et al. (4 authors)
Cellular Signalling
Open Access
Published: Feb 2023
4 citations
4 citations
55 days after retraction
Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies
Ying Wei, Sonia Erfani, David Schweer et al. (18 authors)
Molecular Therapy — Oncolytics
Open Access
Published: Feb 2023
15 citations
15 citations
52 days after retraction
Cell-specific cargo delivery using synthetic bacterial spores
Minsuk Kong, Domenico D’Atri, Maria Teresa Bilotta et al. (13 authors)
Cell Reports
Open Access
Published: Jan 2023
10 citations
10 citations
2 days after retraction
Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
Yoo‐Na Kim, Yun Soo Chung, Ji Hyun Lee et al. (7 authors)
Journal of Gynecologic Oncology
Open Access
Published: Jan 2023
1 citation
1 citation
2 days after retraction
Expression of Concern: The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies
Unknown Authors
PLoS ONE
Open Access
Published: Dec 2022
1 citation
1 citation
Same day as retraction
The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma
Karen L. Talia, Natalie Banet, Natália Buza
Pathology
Published: Nov 2022
20 citations
20 citations
36 days before retraction
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Lana E. Kandalaft, Denarda Dangaj Laniti, George Coukos
Nature reviews. Cancer
Published: Sep 2022
110 citations
110 citations
106 days before retraction
<scp>Aptamer‐siRNA</scp> chimeras: Promising tools for targeting <scp>HER2</scp> signaling in cancer
C. R. Dhanya, Aarcha Shanmugha Mary, Maya Madhavan
Chemical Biology & Drug Design
Published: Sep 2022
7 citations
7 citations
108 days before retraction
Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer
Naamit Deshet‐Unger, Galit Horn, Moran Rawet-Slobodkin et al. (18 authors)
Biomedicines
Open Access
Published: Sep 2022
10 citations
10 citations
114 days before retraction
Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?
Aimee Rendell, Isobel Thomas-Bland, Lee McCuish et al. (6 authors)
Biomedicines
Open Access
Published: Aug 2022
15 citations
15 citations
123 days before retraction
Discovering Common miRNA Signatures Underlying Female-Specific Cancers via a Machine Learning Approach Driven by the Cancer Hallmark ERBB
Katia Pane, Mario Zanfardino, Anna Grimaldi et al. (7 authors)
Biomedicines
Open Access
Published: Jun 2022
6 citations
6 citations
211 days before retraction
Clinical Dose Preparation of [<sup>177</sup>Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [<sup>177</sup>Lu]LuCl<sub>3</sub> for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression
Sreeja Raj Menon, Arpit Mitra, Avik Chakraborty et al. (10 authors)
Cancer Biotherapy and Radiopharmaceuticals
Published: May 2022
5 citations
5 citations
228 days before retraction
Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report
Jing Wu, Yang You, Rongyuan Zhuang et al. (8 authors)
Annals of Translational Medicine
Open Access
Published: Mar 2022
4 citations
4 citations
304 days before retraction
Quick Stats
Total Citations:
90
Years Since Retraction:
2.9 years
Open Access:
Yes
Last Checked:
Jul 24, 2025